Selected article for: "challenge virus and influenza vaccine"
Author: Leung, Ho-Chuen; Chan, Chris Chung-Sing; Poon, Vincent Kwok-Man; Zhao, Han-Jun; Cheung, Chung-Yan; Ng, Fai; Huang, Jian-Dong; Zheng, Bo-Jian
Title: An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus
  • Document date: 2015_4_8
    • ID: 14qckds8_26
    Snippet: To control potential new influenza pandemics, the best measure may be to develop a universal influenza vaccine because no existing vaccines can provide effective cross-protection against a mutated or reassorted novel influenza virus. Current efforts to develop universal vaccines include the development of M2e-based vaccines, HA stem vaccines 29 and M1 VLPs. 30 M2e-based vaccine candidates can provide cross-protection against infections of differe.....
    Document: To control potential new influenza pandemics, the best measure may be to develop a universal influenza vaccine because no existing vaccines can provide effective cross-protection against a mutated or reassorted novel influenza virus. Current efforts to develop universal vaccines include the development of M2e-based vaccines, HA stem vaccines 29 and M1 VLPs. 30 M2e-based vaccine candidates can provide cross-protection against infections of different subtypes of influenza virus. 20, 21, 31 In our previous studies, we showed that an H5N1-M2ebased tetrameric peptide vaccine exhibited promising protection against lethal challenge with different clades of H5N1 virus and other subtypes of influenza virus. 20, 21 In this study, we further demonstrated that this tetrameric peptide vaccine could also offer potent protection against infection with a novel H7N9 influenza virus, which caused a first outbreak from March to June 2013 and a second outbreak from November 2013 to December 2014 in China.

    Search related documents:
    Co phrase search for related documents
    • peptide vaccine and potent protection: 1, 2
    • peptide vaccine and previous study: 1
    • peptide vaccine and tetrameric peptide vaccine: 1, 2
    • peptide vaccine and universal influenza vaccine: 1, 2
    • peptide vaccine and universal influenza vaccine develop: 1
    • peptide vaccine and universal vaccine: 1, 2, 3, 4, 5, 6, 7
    • peptide vaccine and universal vaccine develop: 1, 2
    • peptide vaccine and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
    • potent protection and tetrameric peptide vaccine: 1
    • potent protection and universal influenza vaccine: 1, 2
    • potent protection and universal vaccine: 1, 2, 3, 4
    • potent protection and vaccine candidate: 1, 2, 3, 4, 5, 6
    • previous study and vaccine candidate: 1, 2, 3, 4
    • tetrameric peptide vaccine and universal influenza vaccine: 1
    • tetrameric peptide vaccine and universal vaccine: 1
    • tetrameric peptide vaccine and vaccine candidate: 1
    • universal influenza vaccine and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • universal vaccine and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
    • universal vaccine develop and vaccine candidate: 1, 2, 3